Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.43 |
| ▸ | LPL | P06858 | 3/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 6/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29954610 | 1.00 | CA2 (0.43) | CA2LPLLIPGESR1CA1 | |
| SCHEMBL382234 | 0.79 | LPL (0.39) | CA2LPLLIPGCA1ENPP2 | |
| SCHEMBL3790999 | 0.78 | GAA (0.52) | CA2LPLLIPGCA1ENPP2 | |
| SCHEMBL6726431 | 0.78 | TTR (0.50) | CA2LPLLIPGCA1ENPP2 | |
| SCHEMBL29817989 | 0.75 | CA2 (0.52) | CA2LPLLIPGCA1ENPP2 | |
| SCHEMBL40868 | 0.75 | CA2 (0.52) | CA2LPLLIPGCA1ENPP2 | |
| SCHEMBL21382152 | 0.73 | ENPP2 (0.37) | CA2LPLLIPGCA1ENPP2 | |
| SCHEMBL3786524 | 0.73 | ENPP2 (0.41) | CA2LPLLIPGCA1ENPP2 | |
| SCHEMBL3928671 | 0.73 | CA2 (0.50) | CA2LPLLIPGCA1ENPP2 | |
| SCHEMBL6561636 | 0.71 | ESR1 (0.47) | ESR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626081-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20180244606-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. | 2018-08-30 | — | — | US | disclosed |
| EP-3350158-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | Metacrine, Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| US-10005774-B2 | Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005774-B2 | Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005774-B2 | Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| CN-105555780-B | SYK inhibitors | 吉利德科学公司 | 2018-01-23 | — | — | CN | disclosed |
| EP-3027601-B1 | SYK INHIBITORS | GILEAD SCIENCES INC (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-3027601-B1 | SYK INHIBITORS | GILEAD SCIENCES INC (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2017049172-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2012168162-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | disclosed |
| US-20120316151-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-12-13 | — | — | US | disclosed |
| US-20120309796-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | FIROOZNIA FARIBORZ (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120232078-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2386554-A1 | Compounds active at the histamine H3 receptor | High Point Pharmaceuticals, LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| WO-2011103546-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-08-25 | — | — | WO | disclosed |
| EP-2233470-A1 | Histamine H3 receptor antagonists | High Point Pharmaceuticals, LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090312309-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-12-17 | — | — | US | disclosed |
| EP-1902028-A2 | HISTAMINE H3 RECEPTOR ANTAGONISTS | Novo Nordisk A/S (DK) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007003604-A2 | HISTS1MINE H3 RECEPTOR ANTAGONISTS | NOVO NORDISK A/S (DK) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232078-A1 | Novel Medicaments | HRH3, HRH4, HRH1 | CA2 215/4885LPL 4576/4885LIPG 2029/4885 |
| US-20090312309-A1 | Novel Medicaments | HRH3, HRH4, HRH1 | CA2 215/4885LPL 4576/4885LIPG 2029/4885 |
| US-20180244606-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | CA2 4235/4885LPL 357/4885LIPG 312/4885 |
| US-20120316151-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | CA2 3869/4885LPL 340/4885LIPG 247/4885 |
| US-10626081-B2 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | CA2 4235/4885LPL 357/4885LIPG 312/4885 |
| US-20120309796-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | ACAT2, ACAT1, CYP27A1 | CA2 1495/4885LPL 2357/4885LIPG 2409/4885 |
| US-10005774-B2 | Syk inhibitors | SYK, BTK, LYN | CA2 2768/4885LPL 3143/4885LIPG 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.